I was just reading about the very positive findings for sabizabulin in treating Covid-19 and remembered that several members had been in early clinical trials for prostate cancer (under the name VERU-111).
fortune.com/2022/04/12/expe...
The reason it may work for prostate cancer is similar. In COVID-19, it prevents the virus from forming replicant virus copies. It is a "tubulin disrupter." Tubulin is the structure in all cells that allows the cell to hold its shape. When a cell replicates, it deconstructs the tubulin to allow the cell to form two cells (fission). Then each of the two cells reconstructs the tubulin, which allows the new cells to take shape and survive.
Taxanes (like docetaxel and cabazitaxel) stabilize the tubulin so the cancer cell cannot undergo fission into two cells. Cells that are trying to actively replicate die.
Sabizabulin disrupts the tubulin so that the cell cannot use it to form a stable cell. The hope is that it will be less toxic than taxane chemotherapy while being similarly effective.
In early trials, diarrhea was a common occurrence. The "enteric" cells of the intestines are actively growing, so it isn't surprising to see that side effect. But neutropenia and neuropathathy, which can be troubling side effects of taxane chemo, were not seen. They have adjusted the dose and give it with anti-diarrheal medication in new trials. So far, results have been good - certainly worth pursuing in Phase 3 trials.
aacrjournals.org/clincancer...
Phase 3 trials ("VERACITY") are recruiting throughout the US. To be eligible, you have to have metastatic castration-resistant PCa and have failed at least one of: abiraterone,enzalutamide, darolutamide, or apalutamide. You may have had up to 2 cycles of chemo, but it had to be over a year ago. Patients are randomized 2:1 to either get sabizabulin or one of the other advanced hormone therapies. Here are the details: